OHSU Knight Cancer Institute study uncovers role of gene in renal cancers that don’t respond to current therapies but could be helped by existing FDA-approved drug.
The OHSU study, published in the June 1 edition of Science Translational Medicine, identified a gene called Src that helps certain kidney cancers grow. Discovering that Src plays a role in kidney cancer could help in delivering more effective, individualized treatments to patients, said George Thomas, MD, Associate Professor, Department of Pathology, the study’s senior author and a surgical pathologist at the OHSU Knight Cancer Institute.
The next step, said Dr. Thomas , is initiating clinical trials to test how these tumors respond to drugs already available and approved by the FDA.
- The full OHSU media release is available online